An overview of the efficacy of resveratrol in the management of ischemic heart disease

Ann N Y Acad Sci. 2015 Aug;1348(1):55-67. doi: 10.1111/nyas.12828. Epub 2015 Jul 30.

Abstract

Ischemic heart disease is a leading cause of cardiac dysfunction and subsequent morbidity and mortality around the world. New therapies are required to complement or enhance the existing treatment regimen for the management of ischemic heart disease-related clinical complications. In this regard, compounds derived from natural sources have recently gained attention for their cardioprotective properties. In particular, the potential of food-derived compounds that exhibit medicinal properties (termed nutraceuticals) appears promising, an example being the plant polyphenol resveratrol. In the past two decades, many preclinical and a few pilot clinical studies have shown that resveratrol is beneficial in protecting against cardiovascular disease. In this short review, we will discuss current evidence on the efficacy of resveratrol in preventing or reversing deleterious effects on the heart in the setting of ischemic heart disease.

Keywords: ischemic heart disease; preclinical and clinical trial studies; resveratrol.

Publication types

  • Review

MeSH terms

  • Animals
  • Cardiotonic Agents / pharmacology
  • Cardiotonic Agents / therapeutic use*
  • Coronary Artery Disease / drug therapy*
  • Genetic Therapy
  • Humans
  • Myocardial Reperfusion Injury / prevention & control
  • Resveratrol
  • Stilbenes / pharmacology
  • Stilbenes / therapeutic use*

Substances

  • Cardiotonic Agents
  • Stilbenes
  • Resveratrol